232 related articles for article (PubMed ID: 14627879)
21. Risperidone in children with autism: randomized, placebo-controlled, double-blind study.
Nagaraj R; Singhi P; Malhi P
J Child Neurol; 2006 Jun; 21(6):450-5. PubMed ID: 16948927
[TBL] [Abstract][Full Text] [Related]
22. Clonidine treatment of hyperactive and impulsive children with autistic disorder.
Jaselskis CA; Cook EH; Fletcher KE; Leventhal BL
J Clin Psychopharmacol; 1992 Oct; 12(5):322-7. PubMed ID: 1479049
[TBL] [Abstract][Full Text] [Related]
23. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism.
Fankhauser MP; Karumanchi VC; German ML; Yates A; Karumanchi SD
J Clin Psychiatry; 1992 Mar; 53(3):77-82. PubMed ID: 1548248
[TBL] [Abstract][Full Text] [Related]
24. The effect of risperidone on nursing burden associated with caring for patients with dementia.
Frank L; Kleinman L; Ciesla G; Rupnow MF; Brodaty H
J Am Geriatr Soc; 2004 Sep; 52(9):1449-55. PubMed ID: 15341545
[TBL] [Abstract][Full Text] [Related]
25. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability.
Arnold LE; Farmer C; Kraemer HC; Davies M; Witwer A; Chuang S; DiSilvestro R; McDougle CJ; McCracken J; Vitiello B; Aman MG; Scahill L; Posey DJ; Swiezy NB
J Child Adolesc Psychopharmacol; 2010 Apr; 20(2):83-93. PubMed ID: 20415603
[TBL] [Abstract][Full Text] [Related]
26. Risperidone in children with autism and serious behavioral problems.
McCracken JT; McGough J; Shah B; Cronin P; Hong D; Aman MG; Arnold LE; Lindsay R; Nash P; Hollway J; McDougle CJ; Posey D; Swiezy N; Kohn A; Scahill L; Martin A; Koenig K; Volkmar F; Carroll D; Lancor A; Tierney E; Ghuman J; Gonzalez NM; Grados M; Vitiello B; Ritz L; Davies M; Robinson J; McMahon D;
N Engl J Med; 2002 Aug; 347(5):314-21. PubMed ID: 12151468
[TBL] [Abstract][Full Text] [Related]
27. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Research Units on Pediatric Psychopharmacology Autism Network
Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
29. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study.
Mohammadi MR; Yadegari N; Hassanzadeh E; Farokhnia M; Yekehtaz H; Mirshafiee O; Akhondzadeh S
Clin Neuropharmacol; 2013; 36(6):179-84. PubMed ID: 24201232
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
31. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
[TBL] [Abstract][Full Text] [Related]
32. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
Pandina GJ; Revicki DA; Kleinman L; Turkoz I; Wu JH; Kujawa MJ; Mahmoud R; Gharabawi GM
J Affect Disord; 2009 Nov; 118(1-3):139-46. PubMed ID: 19321206
[TBL] [Abstract][Full Text] [Related]
33. A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism.
Ghanizadeh A; Ayoobzadehshirazi A
Pediatr Neurol; 2015 Jan; 52(1):77-81. PubMed ID: 25451017
[TBL] [Abstract][Full Text] [Related]
34. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety.
Nikoo M; Radnia H; Farokhnia M; Mohammadi MR; Akhondzadeh S
Clin Neuropharmacol; 2015; 38(1):11-7. PubMed ID: 25580916
[TBL] [Abstract][Full Text] [Related]
35. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Aman MG; De Smedt G; Derivan A; Lyons B; Findling RL;
Am J Psychiatry; 2002 Aug; 159(8):1337-46. PubMed ID: 12153826
[TBL] [Abstract][Full Text] [Related]
36. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial.
Ghaleiha A; Mohammadi E; Mohammadi MR; Farokhnia M; Modabbernia A; Yekehtaz H; Ashrafi M; Hassanzadeh E; Akhondzadeh S
Paediatr Drugs; 2013 Dec; 15(6):505-14. PubMed ID: 23821414
[TBL] [Abstract][Full Text] [Related]
37. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
McDougle CJ; Holmes JP; Carlson DC; Pelton GH; Cohen DJ; Price LH
Arch Gen Psychiatry; 1998 Jul; 55(7):633-41. PubMed ID: 9672054
[TBL] [Abstract][Full Text] [Related]
38. l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
Hajizadeh-Zaker R; Ghajar A; Mesgarpour B; Afarideh M; Mohammadi MR; Akhondzadeh S
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):74-81. PubMed ID: 29027815
[TBL] [Abstract][Full Text] [Related]
39. Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures.
Zarcone JR; Hellings JA; Crandall K; Reese RM; Marquis J; Fleming K; Shores R; Williams D; Schroeder SR
Am J Ment Retard; 2001 Nov; 106(6):525-38. PubMed ID: 11708938
[TBL] [Abstract][Full Text] [Related]
40. Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.
Aman M; Rettiganti M; Nagaraja HN; Hollway JA; McCracken J; McDougle CJ; Tierney E; Scahill L; Arnold LE; Hellings J; Posey DJ; Swiezy NB; Ghuman J; Grados M; Shah B; Vitiello B
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):482-93. PubMed ID: 26262903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
